Φορτώνει......
Dasatinib (BMS-35482) interacts synergistically with docetaxel, gemcitabine, topotecan and doxorubicin in ovarian cancer cells with high SRC pathway activation and protein expression
PURPOSE: To explore the activity of dasatinib in combination with docetaxel, gemcitabine, topotecan and doxorubicin in ovarian cancer cells. EXPERIMENTAL DESIGN: Cells with previously determined SRC pathway and protein expression (SRC pathway/SRC protein: IGROV1, both high; SKOV3, both low) were tre...
Αποθηκεύτηκε σε:
| Κύριοι συγγραφείς: | , , , , , , |
|---|---|
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
2014
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3946897/ https://ncbi.nlm.nih.gov/pubmed/24407585 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/IGC.0000000000000056 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|